Akte Therapeutics is developing epigenetic therapies to boost protein production to halt/reverse monogenic diseases. Our platform overcomes the limitations of existing therapeutic approaches to provide treatments for patients in need.
Headquarters:
Australia
Company Type:
SME
Company size:
1-10 Employees
Year Founded:
2023 (2 years)
Address:
SYDNEY, AU
LOW
spending power
